Overview
SLU-PP-332 is an investigational small molecule (technically not a peptide, but commonly grouped with research compounds) developed at Saint Louis University. It activates all three estrogen-related receptors (ERRα, β, γ) — master regulators of mitochondrial biogenesis and oxidative metabolism. In preclinical studies it produced exercise-like adaptations without physical activity, dramatically increasing endurance and reducing fat mass.
Mechanism of action
By agonizing ERRs, SLU-PP-332 upregulates genes responsible for mitochondrial density, fatty-acid oxidation, and slow-twitch (Type I) muscle-fiber characteristics. This shifts cellular metabolism toward fat-burning oxidative pathways — the same adaptations produced by sustained aerobic training.
Reported benefits
- Up to ~50% increase in running endurance in rodent studies
- Significant reduction in fat mass without diet change in models
- Improved insulin sensitivity and glucose handling
- Enhanced mitochondrial density in skeletal muscle
- Resistance to diet-induced obesity in preclinical work
Research dosing
Research protocols typically use 10–50 mg orally per day. Human pharmacokinetic data is limited — this is an early-stage research compound.
Considerations
Very new compound — long-term safety data is not yet established. Effects are mechanistically distinct from GLP-1 agonists like retatrutide, making it of interest for stacking research. Best paired with resistance training to preserve and build lean mass alongside its endurance-oriented adaptations.
Research use only. This article is provided for educational purposes and is not medical advice. Products sold on this website are for laboratory research only and are not intended for human consumption. Not evaluated by the FDA.
Continue reading